ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "complement"

  • Abstract Number: 2797 • 2016 ACR/ARHP Annual Meeting

    Prospective Validation of a Panel of Autoantibodies in Combination with C4d-Bound Complement Activation Products for the Differential Diagnosis of Systemic Lupus Erythematosus

    Daniel J Wallace1, Rosalind Ramsey-Goldman2, Anca D. Askanase3, Susan Manzi4, Joseph Ahearn5, Richard Furie6, Arthur Weinstein7, Chaim Putterman8, Elena Massarotti9, Christopher Collins10, Kenneth Kalunian11, Cristina Arriens12, Stuart L. Silverman13, Smitha Reddy14, Puja Chitkara15, Claudia Ibarra16, Derren Barken17, Roberta Alexander18, John Conklin19 and Thierry Dervieux20, 1Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 2FSM, Northwestern University, Chicago, IL, 3Medicine, Rheumatology, Columbia University Medical Center, New York, NY, 4Lupus Center of Excellence, West Penn Allegheny Health System, Pittsburgh, PA, 5Allegheny Singer Research Institute, Allegheny Health Network, Pittsburgh, PA, 6North Shore University Hospital, Great Neck, NY, 7Rheumatology Section, Washington Hospital Center, Washington, DC, 8Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, 9Rheumatology, Immunology, & Allergy, Harvard Medical School, Brigham & Women's Hosp, Boston, MA, 10MedStar Washington Hospital Center, Washington, DC, 11Center for Innovative Therapy, UCSD School of Medicine, La Jolla, CA, 12Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 13Cedars, Beverly Hills, CA, 14Arthritis Care and Research Center, Inc., Poway, CA, 15Rheumatology, Center For Arthritis and Rheumatologic Excellence, Chula Vista, CA, 16Clinical Laboratory, Exagen Diagnostics, Vista, CA, 17Exagen Diagnostics, Vista, CA, 18Research & Development, Exagen Diagnostics, Vista, CA, 191261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, 20Research and Development, Exagen Diagnostics, Vista, CA

    Background/Purpose: A panel of autoantibodies in combination with C4d-bound complement activation products (CB-CAPs, EC4d and BC4d) has been established as a sensitive and specific testing…
  • Abstract Number: 2856 • 2016 ACR/ARHP Annual Meeting

    Serum C5a Is Elevated in Lupus Nephritis and in Neuropsychiatric Systemic Lupus Erythematosus through Different Mechanisms

    Yuko Sakuma1, Tatsuo Nagai2, Taku Yoshio3 and Shunsei Hirohata4, 1Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, 2Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan, 3Jichi Medical University, Tochigi, Japan, 4Kitasato University School of Medicine, Sagamihara, Japan

    Background/Purpose: Neuropsychiatric manifestation in systemic lupus erythematosus (NPSLE) is one of the most serious complications of the disease. We have recently demonstrated that the breakdown…
  • Abstract Number: 2958 • 2016 ACR/ARHP Annual Meeting

    Hypocomplementemic Urticarial Vasculitis (HUV) Syndrome in Two Geographically Defined Populations of Sweden

    Christopher Sjöwall1, Thomas Mandl2 and Aladdin Mohammad3,4, 1Linköping University, Department of Clinical and Experimental Medicine Rheumatology/AIR, Linköping, Sweden, 2Department of Clinical Sciences Malmö, Lund University, Skåne University Hospital, Rheumatology, Malmö, Sweden, Malmö, Sweden, 3Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Rheumatology, Lund, Sweden, Lund, Sweden, 4Addenbrooke’s Hospital, Vasculitis and Lupus Clinic, Cambridge, UK, Cambridge, United Kingdom

    Background/Purpose: Since first described by McDuffie et al. in 1973, hypocomplementemic urticarial vasculitis (HUV) syndrome has been recognized as a specific autoimmune disorder involving at…
  • Abstract Number: 2992 • 2016 ACR/ARHP Annual Meeting

    In Systemic Lupus Erythematosus with Antiphospholipid Antibodies, Hypocomplementemia Associates with Thrombosis

    Laura Durcan1, Wei Fu2 and Michelle Petri3, 1University of Washington, Seattle, WA, 2Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, 3Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Hypocomplementemia is a common phenomenon in systemic lupus erythematosus (SLE) and antiphospholipid antibody syndrome (APS). Robust mechanistic data implicate complement activation in antiphospholipid antibody…
  • Abstract Number: 819 • 2015 ACR/ARHP Annual Meeting

    Upregulation of Complement C3 and Alpha-2-Macroglobulin in Cerebrospinal Fluid of Neuropsychiatric Systemic Lupus Erythematosus

    Tomoyuki Asano1, Shuzo Sato1, Hiroko Kobayashi1, Yoshinobu Kariya2, Hiromi Ito2, Kyoka Hoshi2, Akioh Yoshihara3, Yoshikazu Ugawa3, Minoru Takahashi4, Hideharu Sekine4, Shunsei Hirohata5, Hiroshi Watanabe1, Hiromasa Ohira1 and Yasuhiro Hashimoto2, 1Gastroenterology and Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan, 2Biochemistry, Fukushima Medical University School of Medicine, Fukushima, Japan, 3Neurology, Fukushima Medical University School of Medicine, Fukushima, Japan, 4Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan, 5Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan

    Background/Purpose: Various autoantibodies have been identified in cerebrospinal fluids (CSF) of neuropsychiatric systemic lupus erythematosus (NPSLE). They are supposed to form immune complex with complement…
  • Abstract Number: 1996 • 2015 ACR/ARHP Annual Meeting

    Complement Activation Predicts Adverse Pregnancy Outcome in Patients with SLE and/or aPL Antibodies

    Jane E. Salmon1,2, Mimi Kim3, Marta Guerra4, Elianna Kaplowitz1, Carl Laskin5, Michelle Petri6, Ware D. Branch7,8, Michael Lockshin9, Lisa R. Sammaritano2, Joan T. Merrill10, Mary D. Stephenson11, Munther Khamashta12, Alan M. Peaceman13, Anne Lynch14 and Jill P. Buyon15, 1Hospital for Special Surgery, New York, NY, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3Biostatistics and Research Design Resource, Albert Einstein Coll Med, Bronx, NY, 4Rheumatology 3rd Fl Rsrch, Hospital for Special Surgery, New York, NY, 5Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, 6Johns Hopkins University School of Medicine, Baltimore, MD, 7University of Utah, Salt Lake City, UT, 8Intermountain Healthcare, Salt Lake City, UT, 9Barbara Volcker Center for Women & Rheumatic Disease, Hospital for Special Surgery, New York, NY, 10Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 11University of Illinois College of Medicine, Chicago, IL, 12Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, 13Northwestern University Feinberg School of Medicine, Chicago, IL, 14Colorado School of Public Health, Aurora, CO, 15NYU School of Medicine, New York, NY

    Background/Purpose: Women with SLE and/or aPL antibodies (SLE/APL) are at increased risk for adverse pregnancy outcomes (APO) yet identification of those destined for complications remains…
  • Abstract Number: 2043 • 2015 ACR/ARHP Annual Meeting

    Cell-Bound Complement Activation Products Have High Sensitivity and Specificity in Childhood-Onset Systemic Lupus Erythematosus and Juvenile Idiopathic Arthritis

    Anca Askanase1, Joyce Hui-Yuen2, John Conklin3, Derren Barken4, Tyler O'Malley5, Xiao Qing Li6, Liza Mariel Bermudez2, Andrew Eichenfield7, Amy J. Starr8, Lisa F. Imundo9,10 and Thierry Dervieux11, 1Columbia University College of Physicians & Surgeons, New York, NY, 2Pediatric Rheumatology, Columbia University Medical Center, New York, NY, 31261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, 4Exagen Diagnostics, Inc., Vista, CA, 5Research and Development, Exagen Diagnostics, Vista, CA, 6Adult Rheumatology, Columbia University Medical Center, New York, NY, 7Morgan Stanley Children's Hospital of NY-Presbyterian, Columbia University, New York, NY, 8Columbia University Medical Center, New York, NY, 9Assoociate Professor of Pediatrics in Medicine - Rheumatology, Columbia University Medical Center, New York, NY, 10New York Presbyterian Hospitsl, Columbia University, New York, NY, 11Research and Development, Exagen Diagnostics, Inc., Vista, CA

    Background/Purpose: Elevated levels of cell-bound complement activation products (C4d deposition on erythrocytes [EC4d] and B lymphocytes [BC4d], CBCAPS) have been demonstrated to be sensitive and…
  • Abstract Number: 2120 • 2015 ACR/ARHP Annual Meeting

    Alterations in Complement C3 and iC3b in SLE Pregnancies

    Marta M. Guerra1, Martin Schmidt2, Elianna Kaplowitz3, Vibeke Strand4 and Jane E. Salmon5, 1Rheumatology 3rd Fl Rsrch, Hospital for Special Surgery, New York, NY, 2Kypha, Inc., St. Louis, MO, 3Hospital for Special Surgery, New York, NY, 4Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, CA, 5Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY

    Background/Purpose: Pregnancy in patients with SLE is associated with increased risk of maternal and fetal complications. Studies in experimental models and humans suggest that complement…
  • Abstract Number: 2180 • 2015 ACR/ARHP Annual Meeting

    Primary Antiphospholipid Syndrome Patients Display Increased Levels of Cell-Bound C4d in Comparison to SLE and Healthy Donors

    Maria Gerosa1,2, Paola Adele Lonati3, Tania Ubiali1, Martina Cornalba1, Maria Orietta Borghi1,4 and Pier Luigi Meroni1,2,5, 1Department of Clinical Sciences and Community Health, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, 2Division of Rheumatology, Division of Rheumatology, Istituto Ortopedico Gaetano Pini, Milan, Italy, 3Laboratory of Immuno-rheumatology, Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Cusano Milanino, Jamaica, 4Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Milan, Italy, 5Laboratory of Immuno-rheumatology, Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Cusano Milanino, Italy

    Background/Purpose: Systemic Lupus Erythematosus (SLE) patients display high levels of the cell-bound complement activation factor C4d deposits on erythrocytes, B lymphocytes and platelets. In particular,…
  • Abstract Number: 198 • 2015 ACR/ARHP Annual Meeting

    CL-L1 and CL-K1 Complement Associated Pattern Recognition Molecules in Systemic Lupus Erythematosus

    Anne Troldborg1, Steffen Thiel2, Lisbeth Jensen3, Magdalena Janina Laska2, Søren Hansen4, Bent Deleuran5,6, Jens Christian Jensenius2 and Kristian Stengaard-Pedersen5, 1clinical medicine, Aarhus University, Aarhus, Denmark, 2Biomedicine, Aarhus University, Aarhus, Denmark, 3Biomedicin, Aarhus University, Aarhus, Denmark, 4Department of cancer and inflammation research, University of Southern Denmark, Odense, Denmark, 5Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 6Biomedicin, Aarhus University, 8000, Denmark

    Background/Purpose: The complement system is one of the key players in the pathogenesis of systemic lupus erythematosus (SLE). Collectin liver 1 (CL-L1) and collectin kidney…
  • Abstract Number: 519 • 2015 ACR/ARHP Annual Meeting

    In Indigenous North Americans at High Risk for RA Complement C5 Level Is Associated with ACPA Positivity and C5a with Transition to Synovitis Even after Correcting for in Vitro Complement Activation Found with Prolonged Sample Storage

    Ceri Richards1, Carol Hitchon2, Xiaobo Meng3, Irene Smolik4, David Robinson4 and Hani S. El-Gabalawy4, 1Internal Medicine, University of Manitoba, Winnipeg, MB, Canada, 2Department of Rheumatology, University of Manitoba, Winnipeg, MB, Canada, 3University of Manitoba, Winnipeg, MB, Canada, 4Arthritis Center, University of Manitoba, Winnipeg, MB, Canada

    Background/Purpose: Complement activation, a key component of innate immunity and activator of adaptive immunity has been linked to RA pathogenesis. Anti-citrullinated peptide antibody (ACPA) and…
  • Abstract Number: 772 • 2015 ACR/ARHP Annual Meeting

    Post-Phlebotomy Stability of Soluble and Cellular Forms of Complement Activation: Implications in SLE Diagnostic Assays

    John Conklin1, Basil Jones2, Tyler O'Malley3, Duncan Poling4, JoAnne Ligayon5, Leilani Wolover6, Ying Qu7, Claudia Ibarra8, Puja Chitkara9 and Thierry Dervieux3, 11261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, 2Exagen Diagnostics, Vista, CA, 3Research and Development, Exagen Diagnostics, Vista, CA, 4Research and Development, Exagen Diagnostics Inc., Vista, CA, 5Flow Cytometry, Exagen Diagnostics Inc., Vista, CA, 6Research and Development, Exagen Diagnostics, Inc., Vista, CA, 7Exagen Diagnostic Inc, Vista, CA, 8Clinical Laboratory, Exagen Diagnostics, Vista, CA, 9Rheumatology, Center For Arthritis and Rheumatologic Excellence, Chula Vista, CA

    Background/Purpose: Deregulation and activation of the classical complement system is known to be associated with systemic lupus erythematosus (SLE). As such, several investigators have proposed…
  • Abstract Number: 2844 • 2014 ACR/ARHP Annual Meeting

    Intracellular Complement C3 Is Exposed on the Cell Surface upon Apoptosis Induction and Participates in the Clearance of Apoptotic Cells By Phagocytes

    Lucrezia Colonna1, Christian Lood1, YuFeng Peng2, Xizhang Sun3, Lena Tanaka3, Sandip Panicker4 and Keith B. Elkon3, 1Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA, 2Rheumatology, University of Washington, Seattle, WA, 3Division of Rheumatology, University of Washington, Seattle, WA, 4True North Therapeutics, South San Francisco, CA

    Background/Purpose The complement system has been viewed as a predominantly serum-derived host defense mechanism with multiple functions, including clearance of apoptotic cells. Defective function of…
  • Abstract Number: 2299 • 2014 ACR/ARHP Annual Meeting

    M-Ficolin and Masp-2 As Inflammatory Markers in Oligoarticular and Systemic Juvenile Idiopathic Arthritis

    Christine Petri1, Steffen Thiel2, Jens Christian Jensenius2 and Troels Herlin1, 1Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, 2Biomedicine, Aarhus University, Aarhus, Denmark

    Background/Purpose The lectin pathway of the complement plays a crucial role in the pathogenesis of various inflammatory processes. The lectin pathway proteins are activated through…
  • Abstract Number: 2171 • 2014 ACR/ARHP Annual Meeting

    Polymorphisms in the FCN1 Gene Coding for M-Ficolin Are Associated with Disease Activity, Radiographic Damage and Are the Strongest Predictors of DAS28 Remission in 180 DMARD naïve Early Rheumatoid Arthritis Patients

    Christian G. Ammitzbøll1, Rudi Steffensen2, Steffen Thiel3, Jens Christian Jensenius3, Kim Horslev-Petersen4, Torkell Ellingsen5,6, Merete Lund Hetland7, Peter Junker8, Mikkel Ostergaard9 and Kristian Stengaard-Pedersen10, 1Arhus University Hospital, Aarhus, Denmark, 2Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark, 3Biomedicine, Aarhus University, Aarhus, Denmark, 4Rheumatology, Research Unit at King Christian X Hospital for Rheumatic Diseases, Graasten, Graasten, Denmark, 5Reumatology, Odense University Hospital, Odense, Denmark, 6Diagnostic Center, Regional Hospital Silkeborg, Silkeborg, Denmark, 7DANBIO, Department of Rheumatology, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, 8Department of Rheumatology, Odense University Hospital, Odense, Denmark, 9Dept of Rheumatology RM, Copenhagen University Hospital, Glostrup, Denmark, 10Rheumatology, Arhus University Hospital, Aarhus, Denmark

    Background/Purpose: M-ficolin is a pattern recognition molecule that collaborates with associated serine proteases as an activator of the complement system. High M-ficolin levels are strongly…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology